VIVUS (VVUS) Lifted to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of VIVUS (NASDAQ:VVUS) from a sell rating to a hold rating in a research report released on Thursday.
According to Zacks, “VIVUS' lead product, Qsymia's sales have been weak since its launch due to high out-of-pocket cost burden for patients, given lack of reimbursement for the product. Low coverage or exclusion of anti-obesity medications in insurance plans is a concern. However, VIVUS is working on boosting Qsymia sales by expanding reimbursement and promotional initiatives. The impact of appointment of John Amos as its new CEO remains to be seen. However, challenges in the obesity market remain. Nonetheless, we are positive on VIVUS’ partnership agreements for Stendra as these provide the company with a steady stream of cash flow from upfront and milestone payments. Shares of the company have outperformed the industry in the past six months.”
Separately, ValuEngine upgraded VIVUS from a sell rating to a hold rating in a research note on Saturday, June 2nd.
VIVUS (NASDAQ:VVUS) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.08). The business had revenue of $14.96 million during the quarter. VIVUS had a negative return on equity of 843.43% and a negative net margin of 72.78%. research analysts forecast that VIVUS will post -4.4 earnings per share for the current year.
An institutional investor recently raised its position in VIVUS stock. Renaissance Technologies LLC boosted its position in shares of VIVUS, Inc. (NASDAQ:VVUS) by 5.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,273,800 shares of the biopharmaceutical company’s stock after acquiring an additional 423,100 shares during the period. Renaissance Technologies LLC owned approximately 7.79% of VIVUS worth $5,833,000 at the end of the most recent quarter.
VIVUS Company Profile
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Read More: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.